Please assess the completion status of the following clinical trial:

Trial Title: Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be between the ages of 18 and 80, inclusive~* Subject must have a diagnosis of prosthetic joint infection (PJI) in a hip or knee joint which has never previously been totally revised because of an infection and for which they are anticipated to undergo a two-stage replacement surgery~* Subject must have a positive microbiological identifier of staphylococci.~* If Subject is female of childbearing potential, must be willing to practice reliable birth control~Exclusion Criteria:~* Subject has permanent intravascular prosthetic material such as heart valves or pacemakers~* Subject has a creatinine clearance (CLCR) \<30 mL/min as determined by the Cockcroft-Gault equation using actual body weight.~* Subject has significant hepatic dysfunction~* Subject has a fungal or mycobacterial PJI~* Subject is known to be HIV-infected with CD4 count ≤ 200 cells/ mm3~* Subject has an abnormal creatine phosphokinase (CPK) (elevated CPK level ≥ 2x ULN) at baseline as measured by central laboratory~* Subject is currently under treatment with chemotherapeutic agents excluding chronic maintenance therapy (e.g. tamoxifen to prevent relapse of primary breast cancer)~* Subject is pregnant, nursing, or lactating.~* Subject is receiving or is expected to receive chronic immunosuppressive therapy during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Daptomycin 6 mg/kg (Type: EXPERIMENTAL): Daptomycin (6 mg/kg every 24 hours \[q24h\]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week).
- Daptomycin 8 mg/kg (Type: EXPERIMENTAL): Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week).
- Comparator (Type: ACTIVE_COMPARATOR): Vancomycin was administered at 1 gram every 12 hours (q12h) as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).

Based on this trial design, predict the completion outcome and termination type (if applicable).